欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:Reprogramming of Human Peripheral Blood Cells to Induced Pl

发布时间:2025-08-31

Reprogramming of Human Peripheral Blood Cells to Induced Pluripotent Stem Cells
Judith Staerk1, Meelad M. Dawlaty1, Qing Gao1, Dorothea Maetzel1, Jacob Hanna1, Cesar A. Sommer2, Gustavo Mostoslavsky2 and Rudolf Jaenisch1, 3, , 

1 The Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
2 Section of Gastroenterology, Department of Medicine and Center for Regenerative Medicine (CReM), Boston University School of Medicine, Boston, MA 02118, USA
3 Department of Biology, Massachusetts Institute of Technology, 31 Ames Street, Cambridge, MA 02139, USA

Embryonic stem cells are pluripotent cells derived from the inner cell mass of the developing embryo that have the capacity to differentiate into every cell type of the adult (Evans and Kaufman, 1981,Martin, 1981,Martin and Evans, 1975,Thomson et al., 1998). The generation of patient-specific pluripotent cells is therefore an important goal of regenerative medicine. A major step to achieve this was the recent discovery that ectopic expression of defined transcription factors induces pluripotency in somatic cells (Lowry et al., 2008,Park et al., 2008b,Takahashi et al., 2007,Yu et al., 2007). Until now, the most common source from which to derive human iPSCs has been skin fibroblasts (Lowry et al., 2008,Park et al., 2008a,Park et al., 2008b,Takahashi et al., 2007,Yu et al., 2009). However, the requirement for skin biopsies and the need to expand fibroblast cells for several passages in vitro represent a hurdle that must be overcome to make iPSC technology broadly applicable. Peripheral blood can be utilized as an easily accessible source of patient tissue for reprogramming. Here we derived iPSCs from frozen human peripheral blood samples. Some of the iPSCs had rearrangements of the T cell receptor (TCR), indicating that T cells can be reprogrammed to pluripotency.

上一篇:西亚试剂:Baxter Submits Application for U.S. FDA Approval of BAX 855
下一篇:《 汽车动力电池行业规范条件》不久将对外正式公布
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4